News

UPCOMING Apr 27, 2025: Come find our poster #328 at the annual AACR conference from 2-5 pm in the session for Antireceptors and Other Biological Therapeutic Agents

Feb 28, 2025: Journal article published in Cancer Letters on "A human-like glutaminase-free asparaginase is highly efficacious in ASNS^low leukemia and solid cancer mouse xenograft models"

Aug 23, 2024: NCI NExT Milestones 2.1-2.5 funding approved for CMC scale-up through pre-IND meeting 

Aug 1, 2024: Awarded $400k Phase 1 National Cancer Institute SBIR small business grant 

July 23, 2024: National Cancer Institute NExT Milestone 1 completed with successful Trust-but-Verify in vivo efficacy studies with head-to-head comparator in three models

May 21, 2024: EbD presented at the MedCity INVEST Conference in Chicago

Oct 17, 2023: EbD presented at the BioInvestor Forum in San Francisco

Sept 5, 2023: EbD co-founder Dr. Schalk recognized as a Notable Woman in STEM by Crain's Chicago Business

Apr 14, 2023: EbD accepted into highly competitive National Cancer Institute NExT program that will move EbD's lead asparaginase asset through IND-enabling studies

Mar 1, 2023: EbD presented at Biocom Global Life Science Partnering and Investor Annual Conference in San Diego

Feb 1, 2023: Journal article published in Haematologica on the "In vivo stabilization of a less toxic asparaginase variant leads to a durable anti-tumor response in acute leukemia".

Jan 11, 2023: EbD presented at the Biotech Showcase during JP Morgan week in San Francisco

Sept 22, 2022: EbD presented at RFU Biomedical Innovation Day in North Chicago, IL

Sept 22, 2022: EbD presented at Illinois IGNITE in Rosemont, IL

July 21, 2022: EbD presented at the Illinois Life Science Showcase in Chicago

Feb 11, 2022: Review published in Cancers on "Novel Insights on the Use of L-Asparaginase as an Efficient and Safe Anti-Cancer Therapy"

July 21, 2021: EbD receives prize in the Rosalind Franklin University/SmartHealth Activator business plan competition

July 19, 2021: EbD co-founder Dr. Schalk semi-finalist in the AIM-HI Venture Competition

Nov 11, 2020: EbD co-founder Dr. Schalk awarded Early Career Innovator Award by the Association of Women in Science-Chicago

Sept 15, 2020: EbD awarded non-dilutive $2M SBIR Phase II grant from the National Cancer Institute

Sept 01, 2020: EbD awarded non-dilutive $400k SBIR Phase I grant from the National Cancer Institute for follow-on next generation asparaginase asset discovery

July 29, 2020: EbD founder and CEO Dr. Lavie featured in Illinois Ventures Q2 2020 roundup

July 01, 2020: EbD co-founder Dr. Schalk named Scientist of the Month by AWIS-Chicago

July 01, 2020: EbD awarded $150k supplemental Phase 1 SBIR grant by the National Cancer Institute

July 23, 2019: EbD co-founders Dr. Schalk and Dr. Nguyen named as 40 Under 40 Chicago Scientists by Halo Cures

July 01, 2019: EbD awarded $300k Phase 1 SBIR small business grant by National Cancer Institute

June 20, 2019: EbD featured as a Success Story by the Chicago Biomedical Consortium

June 19, 2019: Enzyme by Design featured in Crain's Chicago Business

Feb 4, 2019: Awarded $50k I-corp grant to participate in the National Institutes of Health nation-wide program to conduct customer discovery interviews with >100 experts 

Jan 11, 2019: Completed the National Science Foundation I-corp program through the University of Chicago's Polsky Center for Entrepreneurship and Education

Sep 20, 2018: Awarded $300k Phase 1 small business SBIR grant from the National Cancer Institute

July 01, 2018: Awarded $300k Phase 1 small business SBIR grant from the National Cancer Institute

Mar 03, 2018: EbD CEO and founder featured in news article "Meet our researchers- For Lavie, Father knows best"